Back to User profile » Dr Margherita Andretta
Papers published by Dr Margherita Andretta:
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
Fagiuoli S, Toniutto P, Coppola N, Ancona DD, Andretta M, Bartolini F, Ferrante F, Lupi A, Palcic S, Rizzi FV, Re D, Alvarez Nieto G, Hernandez C, Frigerio F, Perrone V, Degli Esposti L, Mangia A
Therapeutics and Clinical Risk Management 2023, 19:57-65
Published Date: 18 January 2023
Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data
Perrone V, Giacomini E, Sangiorgi D, Andretta M, Bartolini F, Lupi A, Ferrante F, Palcic S, Re D, Degli Esposti L
Risk Management and Healthcare Policy 2022, 15:1483-1489
Published Date: 28 July 2022
Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources
Perrone V, Veronesi C, Dovizio M, Ancona DD, Andretta M, Bartolini F, Cavaliere A, Chinellato A, Ciaccia A, Cillo M, De Francesco A, Enieri N, Ferrante F, Gentile S, Procacci C, Ubertazzo L, Vercellone A, Lucatelli D, Procaccini M, Degli Esposti L
ClinicoEconomics and Outcomes Research 2022, 14:513-521
Published Date: 28 July 2022
Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
Degli Esposti L, Veronesi C, Ancona DD, Andretta M, Bartolini F, Drei A, Lupi A, Palcic S, Re D, Rizzi FV, Giacomini E, Perrone V
ClinicoEconomics and Outcomes Research 2022, 14:139-147
Published Date: 10 March 2022
Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy
Perrone V, Sangiorgi D, Andretta M, Ducci G, Forti B, Francesa Morel PC, Gambera M, Maina G, Mencacci C, Mennini FS, Zanalda E, Degli Esposti L
ClinicoEconomics and Outcomes Research 2021, 13:629-635
Published Date: 5 July 2021
Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia
Perrone V, Giacomini E, Andretta M, Arenare L, Cillo MR, Latini M, Mecozzi A, Pagliaro R, Vercellone A, Degli Esposti L
Therapeutics and Clinical Risk Management 2021, 17:617-622
Published Date: 8 June 2021